MARKET

AGLE

AGLE

Aeglea Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.41
+0.11
+1.33%
After Hours: 8.41 0 0.00% 16:00 11/21 EST
OPEN
8.37
PREV CLOSE
8.30
HIGH
8.44
LOW
8.17
VOLUME
43.72K
TURNOVER
--
52 WEEK HIGH
9.45
52 WEEK LOW
5.99
MARKET CAP
243.77M
P/E (TTM)
-3.4785
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AGLE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

AGLE News

  • Aeglea BioTherapeutics EPS misses by $0.12
  • seekingalpha.11/06 18:39
  • Aeglea BioTherapeutics Q3 EPS $(0.66) Down From $(0.54) YoY
  • Benzinga.11/06 13:54
  • Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights
  • GlobeNewswire.11/06 13:30
  • Aeglea BioTherapeutics Strengthens Leadership Team with Appointment of Ravi M. Rao as Chief Medical Officer and Michael C. Hanley as Chief Commercial Officer
  • GlobeNewswire.11/04 13:30

More

Industry

Biotechnology & Medical Research
-0.31%
Pharmaceuticals & Medical Research
+0.32%

Hot Stocks

Name
Price
%Change

About AGLE

Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company's product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.
More

Webull offers Aeglea Bio Therapeutics Inc (AGLE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.